Daiichi Sankyo placed a partial hold on recruitment and enrollment in the phase III IDeate‑Lung02 study of the antibody‑drug conjugate ifinatamab deruxtecan after an unexpected rise in grade 5 interstitial lung disease (ILD) events, including fatalities. The company voluntarily paused new enrollment while investigating the safety signal and reviewing ongoing patient management procedures. The move directly affects a partnered development pathway and raises broader questions about ADC pulmonary toxicity profiles. Regulators will expect comprehensive event adjudication and mitigation plans before the trial resumes or data are used in regulatory submissions.